*This seminar has been cancelled due to insufficient interest.

Baker McKenzie lawyers and Austrade, the Australian Trade Commission, are pleased to invite you to attend a complimentary seminar at the Australian Embassy in Tokyo. The seminar will discuss Japanese investment in Australian healthcare and clinical trials.

Speakers will outline opportunities in Australia for Japanese investors and Japanese healthcare companies, and will summarise relevant legal regulation. They will comment on the advantages for Japanese companies of conducting clinical trials in Australia.

The function will conclude with a selection of fine wines, canapés and the opportunity to network with the panel and guests

RSVP is essential, to ensure access to the embassy,and we kindly ask you to do so by using the link below.

If you would like to attend this briefing, please register via the RSVP link provided below.


  • Deadline for seminar registration is Tuesday 5 June 2018.
  • Number of seats is limited. In case of overcapacity, attendance will be decided by lot.
  • If capacity is reached, we may close registration without notice.

If you are unable to register online, please email the following information:
Name, Company, Position, Address, Telephone, Email Address

If you have any questions about this seminar, please email us.

We look forward to seeing many of you at the seminar.

Australian Healthcare

Today healthcare is Australia’s fourth biggest contributor to GDP.  Australia was recently ranked as having the second best health system overall in the developed world, due to health outcomes and administrative efficiency. The sector is also attractive to foreign investors, as Australia has a reputation as a producer of high quality and rigorously tested health products.

Currently, the healthcare industries are Australia’s biggest employer, employing 13 percent of the Australian work force.

It is expected that Australia’s ageing population and rising middle class will buoy demand for smart, connected medical technologies such as personalised implants, bionics and 24/7 monitoring devices.

Australia is establishing itself as a centre for drug development and clinical trials.  It is regarded as one of the best places in the world to conduct clinical trials. It boasts world-class medical research and healthcare infrastructure, a sound socio-economic environment, and a strong intellectual property regime.

Lastly, the Australian Government has introduced a range of measure to encourage Australia’s biotechnology and research industry, having established a variety of funds for medical research.


Sabrina Chan
Sabrina Chan
Senior Associate (Sydney)

Event Details

Date Tuesday 12 June, 2018
Time Seminar 3:30 pm – 6:00 pm (Registration starts at 1:30 pm)
Cocktail reception 6:00 pm – 7:30 pm
Venue Astralian Embassy, Tokyo
2-1-14 Mita, Minato-ku, Tokyo 108-8361
Fee Complimentary (Registration is required for this event)
Language English and Japanese (Simultaneous interpretation will be provided.)
Contact Tel: 03 6271 9900 (Mishima, Yamashita)
email: seminar.tokyo@bakermckenzie.com






Austrade, the Australian Trade Commission
Baker & Mckenzie (Gaikokuho Joint Enterprise)


and more

Practice Focus